These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21270339)

  • 1. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease.
    Gatza E; Wahl DR; Opipari AW; Sundberg TB; Reddy P; Liu C; Glick GD; Ferrara JL
    Sci Transl Med; 2011 Jan; 3(67):67ra8. PubMed ID: 21270339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.
    Glick GD; Rossignol R; Lyssiotis CA; Wahl D; Lesch C; Sanchez B; Liu X; Hao LY; Taylor C; Hurd A; Ferrara JL; Tkachev V; Byersdorfer CA; Boros L; Opipari AW
    J Pharmacol Exp Ther; 2014 Nov; 351(2):298-307. PubMed ID: 25125579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
    Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
    J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death.
    Hartwig UF; Robbers M; Wickenhauser C; Huber C
    Blood; 2002 Apr; 99(8):3041-9. PubMed ID: 11929798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
    Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T
    Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mouse T cells engineered to display on their surface a novel form of FasL protein undergo apoptosis when stimulated with alloantigens: implications for graft-versus-host disease.
    Yolcu ES; Singh NP
    Transplant Proc; 2013 Jun; 45(5):1850-2. PubMed ID: 23769056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
    He S; Wang J; Kato K; Xie F; Varambally S; Mineishi S; Kuick R; Mochizuki K; Liu Y; Nieves E; Mani RS; Chinnaiyan AM; Marquez VE; Zhang Y
    Blood; 2012 Feb; 119(5):1274-82. PubMed ID: 22117046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation.
    Nguyen HD; Chatterjee S; Haarberg KM; Wu Y; Bastian D; Heinrichs J; Fu J; Daenthanasanmak A; Schutt S; Shrestha S; Liu C; Wang H; Chi H; Mehrotra S; Yu XZ
    J Clin Invest; 2016 Apr; 126(4):1337-52. PubMed ID: 26950421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity.
    Hill GR; Teshima T; Rebel VI; Krijanovski OI; Cooke KR; Brinson YS; Ferrara JL
    J Immunol; 2000 Jan; 164(2):656-63. PubMed ID: 10623807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.
    Sofi MH; Wu Y; Schutt SD; Dai M; Daenthanasanmak A; Heinrichs Voss J; Nguyen H; Bastian D; Iamsawat S; Selvam SP; Liu C; Maulik N; Ogretmen B; Jin J; Mehrotra S; Yu XZ
    J Clin Invest; 2019 May; 129(7):2760-2774. PubMed ID: 31045571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation.
    Alpdogan SO; Lu SX; Patel N; McGoldrick S; Suh D; Budak-Alpdogan T; Smith OM; Grubin J; King C; Goldberg GL; Hubbard VM; Kochman AA; van den Brink MR
    Blood; 2008 Dec; 112(12):4755-64. PubMed ID: 18815289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
    J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.
    Na IK; Lu SX; Yim NL; Goldberg GL; Tsai J; Rao U; Smith OM; King CG; Suh D; Hirschhorn-Cymerman D; Palomba L; Penack O; Holland AM; Jenq RR; Ghosh A; Tran H; Merghoub T; Liu C; Sempowski GD; Ventevogel M; Beauchemin N; van den Brink MR
    J Clin Invest; 2010 Jan; 120(1):343-56. PubMed ID: 19955659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.